Abstract:Abstract The NF-E2 p45-related factor 2 (Nrf2) regulates cytoprotective genes that contain an antioxidant response element (ARE) in their promoters. To investigate whether anticancer drugs can induce ARE-driven gene expression, we have developed a stable human mammary MCF7-derived reporter cell line called AREc32, which contains a luciferase gene construct controlled by eight copies of the cis-element. In these cells, luciferase activity was increased up to 50-fold following treatment with 50 μmol/L tert-butylhydroquinone (t-BHQ). Basal and inducible luciferase activities in AREc32 cells were increased by forced overexpression of Nrf2 and reduced by knockdown of endogenous Nrf2 expression with RNA interference. Depletion of cellular reduced glutathione (GSH) by treatment of AREc32 cells with l-buthionine-S,R-sulfoximine (BSO) did not influence basal levels of luciferase activity, but pretreatment with BSO augmented induction of luciferase activity by t-BHQ. Induction of reporter activity by t-BHQ in AREc32 cells was suppressed markedly by the antioxidants N-acetylcysteine and GSH but only modestly by vitamins C or E, suggesting that ARE-luciferase expression is induced primarily by thiol-active electrophiles rather than free radicals. The anticancer drugs cisplatin, etoposide, mitoxantrone, chlorambucil, melphalan, and carmustine [1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)] weakly induced luciferase activity in AREc32 cells. Moreover, treatment of AREc32 cells with BSO immediately before exposure to anticancer drugs enhanced induction of ARE-driven luciferase activity by cisplatin, BCNU, chlorambucil, and melphalan and also induced endogenous AKR1C (AKR1C refers to AKR1C1 and AKR1C2), a target gene of Nrf2. Our findings show that Nrf2 can be activated by certain anticancer agents, and this will influence the effectiveness of chemotherapy. (Cancer Res 2006; 66(22): 10983-94)

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

The Role of Nrf2-ARE Signal Pathway in Tumorigenesis and Drug Resistance

Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

Generation of A Stable Antioxidant Response Element-Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

The role of Nrf2 in carcinogenesis

Retinoid X Receptor Regulates Nur77/Thyroid Hormone Receptor 3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Retinoid X Receptor Regulates Nur77/TR3-Dependent Apoptosis by Modulating Its Nuclear Export and Mitochondrial Targeting

Targeting Truncated RXRα for Cancer Therapy.

The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells